Equities research analysts at Needham & Company LLC assumed coverage on shares of Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) in a report issued on Tuesday,Briefing.com Automated Import reports. The firm set a "buy" rating and a $15.00 price target on the biopharmaceutical company's stock. Needham & Company LLC's price target would indicate a potential upside of 96.08% from the stock's current price.
Several other research analysts also recently commented on the company. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. JMP Securities set a $19.00 target price on Ocular Therapeutix in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $16.29.
Check Out Our Latest Research Report on OCUL
Ocular Therapeutix Stock Performance
Shares of Ocular Therapeutix stock opened at $7.65 on Tuesday. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix has a 52 week low of $4.06 and a 52 week high of $11.78. The firm has a market capitalization of $1.22 billion, a P/E ratio of -5.80 and a beta of 1.34. The company has a 50 day moving average price of $7.73 and a 200 day moving average price of $8.85.
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Sell-side analysts expect that Ocular Therapeutix will post -0.98 EPS for the current year.
Insiders Place Their Bets
In related news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Donald Notman sold 11,119 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the sale, the insider now owns 193,444 shares in the company, valued at $1,510,797.64. The trade was a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,895 shares of company stock valued at $283,772. 3.50% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in Ocular Therapeutix in the fourth quarter valued at approximately $28,000. Atlas Capital Advisors Inc. acquired a new position in shares of Ocular Therapeutix in the fourth quarter worth about $43,000. AlphaQuest LLC purchased a new position in Ocular Therapeutix in the fourth quarter valued at about $53,000. Tower Research Capital LLC TRC grew its stake in Ocular Therapeutix by 2,045.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 8,446 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Ocular Therapeutix in the 4th quarter valued at approximately $90,000. Hedge funds and other institutional investors own 59.21% of the company's stock.
About Ocular Therapeutix
(
Get Free Report)
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ocular Therapeutix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.
While Ocular Therapeutix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
